PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
3986.96%
Revenue growth of 3986.96% while AVXL is flat. Bruce Berkowitz would check if a small edge can widen further.
804.39%
Gross profit growth of 804.39% while AVXL is zero. Bruce Berkowitz would see if minimal improvements could expand further.
35.83%
EBIT growth above 1.5x AVXL's 4.31%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
35.83%
Operating income growth above 1.5x AVXL's 4.31%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
36.40%
Net income growth above 1.5x AVXL's 7.13%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
37.84%
EPS growth above 1.5x AVXL's 6.67%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
37.84%
Diluted EPS growth above 1.5x AVXL's 6.67%. David Dodd would see if there's a robust moat protecting these shareholder gains.
2.81%
Share count expansion well above AVXL's 0.29%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
2.81%
Diluted share change of 2.81% while AVXL is zero. Bruce Berkowitz might see a minor difference that could widen over time.
No Data
No Data available this quarter, please select a different quarter.
-14.43%
Negative OCF growth while AVXL is at 54.38%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-14.57%
Negative FCF growth while AVXL is at 54.38%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1885.22%
Negative 10Y OCF/share CAGR while AVXL stands at 71.70%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
90.95%
5Y OCF/share CAGR above 1.5x AVXL's 43.92%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
81.42%
3Y OCF/share CAGR above 1.5x AVXL's 48.70%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
-991.23%
Negative 10Y net income/share CAGR while AVXL is at 55.98%. Joel Greenblatt sees a major red flag in long-term profit erosion.
94.68%
Positive 5Y CAGR while AVXL is negative. John Neff might view this as a strong mid-term relative advantage.
84.15%
3Y net income/share CAGR above 1.5x AVXL's 9.54%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
1611.09%
10Y equity/share CAGR above 1.5x AVXL's 618.86%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
-55.02%
Negative 5Y equity/share growth while AVXL is at 285.55%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
127.30%
Below 50% of AVXL's 418.15%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.25%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-8.96%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-36.45%
We’re deleveraging while AVXL stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-19.33%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-34.65%
We cut SG&A while AVXL invests at 6.53%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.